Trials / Completed
CompletedNCT00163514
Safety and Effectiveness of Ciclesonide Nasal Spray in Children (6 to 11 Years) With Perennial Allergic Rhinitis (BY9010/M1-403)
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Trial Designed to Assess the Efficacy and Safety of Ciclesonide Applied as a Nasal Spray at Three Dose Levels (200 Mcg, 100 Mcg, or 25 Mcg, Once Daily) in the Treatment of Perennial Allergic Rhinitis (PAR) in Patients 6-11 Years of Age
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 636 (planned)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 6 Years – 11 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the safety and effectiveness of ciclesonide nasal spray as compared with placebo (inactive substance) nasal spray in relieving symptoms of perennial allergic rhinitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ciclesonide |
Timeline
- Start date
- 2004-05-01
- Primary completion
- 2005-07-01
- Completion
- 2005-07-01
- First posted
- 2005-09-14
- Last updated
- 2016-12-02
Locations
74 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00163514. Inclusion in this directory is not an endorsement.